Zomedica Q3 net loss $6.3M; revenue minimal from TRUFORMA launch; cash $271.4M

Zomedica Corp.

2022-Q3 EPS reported -$0.05 revenue$52,000

Net loss of $6.3M ($0.01/share) vs $5.0M loss in Q3 2020; nine-month loss $15.1M.
Revenue from TRUFORMA products was $22,514; commercial launch began March 2021.
Cash and equivalents $271.4M at Sept 30, 2021; pro forma after PulseVet acquisition ~$199.5M.
SG&A expense rose 166% to $6.1M, driven by share-based compensation and PulseVet deal costs.
R&D expense fell 89% to $0.3M as initial TRUFORMA assays completed; development shifts to commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.